Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDXCNASDAQ:DERMNASDAQ:DNTHNASDAQ:IOVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXCChromaDex$6.16$2.31▼$9.18$611.50M2.21777,596 shs554,788 shsDERMJourney Medical$7.00+2.6%$6.59$3.46▼$8.24$161.73M0.8683,916 shs64,670 shsDNTHDianthus Therapeutics$18.42+0.3%$19.13$13.37▼$32.27$592.39M1.48273,124 shs234,992 shsIOVAIovance Biotherapeutics$1.78+1.7%$2.97$1.64▼$12.51$594.40M1.068.64 million shs7.85 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXCChromaDex0.00%0.00%0.00%+45.11%+148.11%DERMJourney Medical+2.64%+1.01%-6.42%+34.87%+97.18%DNTHDianthus Therapeutics+0.33%-6.45%-14.56%-22.18%-20.09%IOVAIovance Biotherapeutics+1.71%+7.23%-44.20%-69.20%-82.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDXCChromaDex2.8487 of 5 stars3.50.00.04.00.00.01.9DERMJourney Medical1.8643 of 5 stars3.62.00.00.01.01.70.6DNTHDianthus Therapeutics1.1681 of 5 stars3.60.00.00.02.10.80.0IOVAIovance Biotherapeutics4.4318 of 5 stars4.31.00.04.22.82.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDXCChromaDex 3.00Buy$9.03∞ UpsideDERMJourney Medical 3.20Buy$9.8841.07% UpsideDNTHDianthus Therapeutics 3.22Buy$53.00187.73% UpsideIOVAIovance Biotherapeutics 2.50Moderate Buy$13.30647.19% UpsideCurrent Analyst Ratings BreakdownLatest DERM, DNTH, CDXC, and IOVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025IOVAIovance BiotherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$17.00 ➝ $2.005/15/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/13/2025DNTHDianthus TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$58.00 ➝ $50.005/13/2025DNTHDianthus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.005/12/2025IOVAIovance BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $8.005/12/2025IOVAIovance BiotherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $10.005/12/2025IOVAIovance BiotherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.005/12/2025IOVAIovance BiotherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/9/2025IOVAIovance BiotherapeuticsBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/9/2025IOVAIovance BiotherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform5/9/2025IOVAIovance BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $25.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDXCChromaDex$99.60M0.00N/AN/A$0.38 per share0.00DERMJourney Medical$56.24M2.88$0.25 per share28.37$1.05 per share6.67DNTHDianthus Therapeutics$6.52M90.80N/AN/A$11.40 per share1.62IOVAIovance Biotherapeutics$212.68M2.79N/AN/A$2.28 per share0.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDXCChromaDex-$4.94M$0.10787.290.00N/A1.62%4.85%2.70%N/ADERMJourney Medical-$3.85M-$0.39N/AN/AN/A-31.74%-132.10%-26.90%8/11/2025 (Estimated)DNTHDianthus Therapeutics-$43.56M-$2.88N/AN/AN/A-1,250.32%-21.68%-20.88%N/AIOVAIovance Biotherapeutics-$444.04M-$1.24N/AN/AN/A-451.25%-58.43%-45.48%N/ALatest DERM, DNTH, CDXC, and IOVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DERMJourney Medical-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million5/12/2025Q1 2025DNTHDianthus Therapeutics-$0.86-$0.82+$0.04-$0.82$0.81 million$1.16 million5/8/2025Q1 2025IOVAIovance Biotherapeutics-$0.25-$0.36-$0.11-$0.36$83.40 million$49.32 million3/26/2025Q4 2024DERMJourney Medical-$0.22$0.08+$0.30$0.08$14.21 million$14.30 million3/11/2025Q4 2024DNTHDianthus Therapeutics-$0.85-$0.81+$0.04-$0.81$1.40 million$1.33 million2/27/2025Q4 2024IOVAIovance Biotherapeutics-$0.26-$0.26N/A-$0.26$72.17 million$73.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDXCChromaDexN/AN/AN/AN/AN/ADERMJourney MedicalN/AN/AN/AN/AN/ADNTHDianthus TherapeuticsN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDXCChromaDexN/A2.952.35DERMJourney Medical1.811.381.03DNTHDianthus TherapeuticsN/A18.3018.30IOVAIovance BiotherapeuticsN/A4.223.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDXCChromaDex15.41%DERMJourney Medical7.25%DNTHDianthus Therapeutics47.53%IOVAIovance Biotherapeutics77.03%Insider OwnershipCompanyInsider OwnershipCDXCChromaDex9.64%DERMJourney Medical15.03%DNTHDianthus Therapeutics8.15%IOVAIovance Biotherapeutics12.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDXCChromaDex12077.75 million69.02 millionOptionableDERMJourney Medical9023.10 million18.14 millionN/ADNTHDianthus Therapeutics8032.16 million24.70 millionOptionableIOVAIovance Biotherapeutics500333.93 million267.90 millionOptionableDERM, DNTH, CDXC, and IOVA HeadlinesRecent News About These CompaniesFORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC Continues Lead Plaintiff Search for Iovance Biotherapeutics, Inc. (IOVA) Securities Fraud Class ActionMay 23 at 10:50 PM | prnewswire.comClass Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) Over Securities Violations - Contact Levi & Korsinsky TodayMay 23 at 6:00 PM | accessnewswire.comIOVA Class Action Alert: Robbins LLP Reminds IOVA Stockholders of the Lead Plaintiff Deadline in the Iovance Biotherapeutics, Inc. Class ActionMay 23 at 5:35 PM | accessnewswire.comClass Action Alert: Levi & Korsinsky Reminds Iovance (IOVA) Investors of July 14, 2025 DeadlineMay 23 at 5:30 PM | accessnewswire.comInvestor Alert: Deadline Approaching to Join Iovance Biotherapeutics, Inc. (IOVA) Class Action - Contact Levi & KorsinskyMay 23 at 4:45 PM | accessnewswire.comClass Action Lawsuit Filed: Iovance Biotherapeutics, Inc. (IOVA) - Join by July 14, 2025 - Contact Levi & KorsinskyMay 23 at 3:40 PM | accessnewswire.comIOVA FRAUD NEWS: Iovance Biotherapeutics, Inc. is Being Sued for Securities Fraud; Investors That Lost Money Are Urged to Contact BFA Law by July 14 Court DeadlineMay 23 at 3:18 PM | accessnewswire.comIovance Biotherapeutics (IOVA) Faces Investor Lawsuit Over Growth Projections Following Stock Plunge - Hagens BermanMay 23 at 12:30 PM | accessnewswire.comContact Levi & Korsinsky by July 14, 2025 to Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA)May 23 at 12:30 PM | accessnewswire.comScott+Scott Attorneys at Law LLP Reminds Investors of the Ongoing Action Against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)May 23 at 12:03 PM | globenewswire.comIovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitMay 23 at 12:00 PM | prnewswire.comIovance Biotherapeutics, Inc.: Iovance Announces Five-year Results of Amtagvi (lifileucel) in Patients with Advanced Melanoma at ASCO Annual MeetingMay 23 at 11:31 AM | finanznachrichten.deClass Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) Over Securities Violations - Contact Levi & Korsinsky TodayMay 23 at 10:15 AM | accessnewswire.comIOVA Investors Have the Opportunity to Lead the Iovance Biotherapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLPMay 23 at 10:03 AM | globenewswire.comIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmMay 23 at 9:54 AM | prnewswire.comRecover Investment Losses: Levi & Korsinsky Files Class Action Against Iovance Biotherapeutics, Inc. (IOVA)May 23 at 8:30 AM | accessnewswire.comIOVA FRAUD ALERT: Lose Money when Iovance Biotherapeutics, Inc. Stock Dropped 44%? Contact BFA Law by July 14 Class Action Deadline (NASDAQ:IOVA)May 23 at 8:07 AM | globenewswire.comDid You Lose Money on Iovance Biotherapeutics, Inc. (IOVA)? Levi & Korsinsky Urges Investors to Act Before July 14, 2025May 23 at 7:15 AM | accessnewswire.comIOVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Iovance Biotherapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!May 23 at 7:00 AM | accessnewswire.comClass Action Alert: Levi & Korsinsky Reminds Iovance (IOVA) Investors of July 14, 2025 DeadlineMay 22 at 11:45 PM | accessnewswire.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) is Soleus Capital Management L.P.'s 8th Largest PositionMay 21 at 8:13 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDERM, DNTH, CDXC, and IOVA Company DescriptionsChromaDex NASDAQ:CDXCChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.Journey Medical NASDAQ:DERM$7.00 +0.18 (+2.64%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$7.01 +0.01 (+0.14%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Dianthus Therapeutics NASDAQ:DNTH$18.42 +0.06 (+0.33%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$18.42 +0.00 (+0.03%) As of 05/23/2025 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Iovance Biotherapeutics NASDAQ:IOVA$1.78 +0.03 (+1.71%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.78 0.00 (0.00%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
